LPSN LivePerson Inc

UNITED STATES

SECURITIES & EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No.  )*

LivePerson, Inc.

(Name of Issuer)

Common Stock, par value $0.001 par value per share

(Title of Class of Securities)

538146101

(CUSIP Number)

Alexander R. Slusky

Vector Capital Management, L.P.

One Market Street

Steuart Tower, 23^rd Floor

San Francisco, CA 94105

(415) 293-5000

Copy to:

Paul Hastings LLP

101 California Street, Forty-Eighth Floor

San Francisco, CA 94111

(415) 856-7000

Attention: Steve Camahort and Dana Kromm

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 28, 2024

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 13d-7(b) for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

- 3 -

- 4 -

- 5 -

The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. The information set forth in the Exhibits and Schedule attached hereto is expressly incorporated herein by reference and the response to each item of this Schedule 13D is qualified in its entirety by the provisions of such Exhibits and Schedule.

The class of equity securities to which this Schedule 13D relates is the common stock, par value $0.001 per share (“Common Stock”), of LivePerson, Inc., a Delaware corporation (the “Issuer”). The Issuer’s principal executive office is located at 530 7th Ave, Floor M1, New York, New York 10018. The Reporting Persons (as defined below) are filing this Schedule 13D pursuant to the requirements of Rule 13d-1(e)(1) under the Act.

A Joint Filing Agreement among the Reporting Persons is attached hereto as Exhibit 99.1.

This Schedule 13D relates to the shares of Common Stock held by VCVI. VCM is the investment manager of VCVI. VCLLC is the general partner of VCM. Mr. Slusky is the managing member of VCLLC and Chief Investment Officer of VCM.

The 10,899,456 shares of Common Stock beneficially owned by the Reporting Person were acquired in open market transactions for an aggregate purchase price of $32,459,957. The source of funds for these purchases was the working capital of Vector.

- 6 -

(a) – (j)

The Reporting Persons originally acquired the securities reported herein for investment purposes as they believed that the securities, at market prices when acquired, represented an attractive investment opportunity. The Reporting Persons have in the past engaged in discussions with management, the board of directors and other relevant parties concerning the business, operations, strategy and future plans of the Issuer and with other stockholders concerning the business and operations of the Issuer.

At the invitation of the Issuer, on February 28, 2024, the Reporting Person and the Issuer entered into a letter agreement (the “Confidentiality Agreement”), for the purpose of facilitating the Issuer providing and discussing with the Reporting Person certain non-public information with respect to the Company’s operations, performance and plans. The term of the Confidentiality Agreement expired on March 4, 2024, upon the filing of the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. In order to allow such discussions to continue, the Reporting Persons and the Issuer are discussing entering into a new confidentiality agreement, which would likely include additional provisions covering customary additional topics beyond those included in the Confidential Agreement (e.g. a longer term and employee non-solicit and standstill terms).

The Reporting Persons intend to continue to review their investment in the Issuer on a continuing basis and may in the future continue to engage in discussions with management, the board of directors and other relevant parties and/or engage in discussions with other stockholders, in each case concerning the business, operations, board composition, management, strategy and future plans of the Issuer. Depending upon numerous factors, including, without limitation, general market and economic conditions, ongoing evaluation of the Issuer’s business, financial condition, operations and prospects, the relative attractiveness of alternative business and investment opportunities, the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable and other future developments, the Reporting Persons may endeavor to (i) increase or decrease their respective positions in the Issuer through, among other things, the purchase or sale of securities of the Issuer on the open market or in private primary and/or secondary transactions on such terms and at such times as the Reporting Persons may deem advisable, (ii) enter into transactions that increase or hedge their economic exposure to the Common Stock without affecting their beneficial ownership of shares of Common Stock and/or (iii) otherwise change their intention with respect to any and all matters referred to in Item 4 of Schedule 13D.

Except as set forth in this Item 4, none of the Reporting Persons currently has any specific plans or proposals which relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, although the Reporting Persons may, at any time and from time to time, review or reconsider their position, change their purpose and/or formulate plans or proposals with respect thereto. As a result of these activities, one or more of the Reporting Persons may suggest or take a position with respect to potential changes in the business, operations, strategy and future plans of the Issuer, which suggestions or positions may include one or more plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of Schedule 13D.

(a) Each of the Reporting Persons’ current ownership in the Issuer and the Issuer’s Common Stock is set forth on the cover pages to this Schedule 13D and is incorporated by reference herein. The ownership percentages reported in this Schedule 13D are based on 88,111,015 shares of the Issuer’s Common Stock issued and outstanding on February 23, 2024, as reported in the Issuer’s Form 10-K dated March 4, 2024.

- 7 -

(b) The number of shares of Common Stock of the Issuer that may be deemed to be beneficially owned by each of the Reporting Persons with respect to which there is (i) sole voting power, (ii) shared voting power, (iii) sole dispositive power, and (iv) shared dispositive power is as set forth below.

(c) Not applicable.

(d) Not applicable.

(e) Not applicable.

The information set forth in Items 3, 4 and 5 above is incorporated herein by reference in its entirety into this Item 6.

In connection with jointly filing this Schedule 13D pursuant to the provisions of Rule 13d-1(k)(1) under the Act, the Reporting Persons entered into a Joint Filing Agreement, which is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Except as otherwise described in this Schedule 13D, there are no contracts, arrangements, understandings or similar relationships with respect to the securities of the Issuer among or between the Reporting Persons or any other person or entity.

- 8 -

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Exhibit 99.1

Joint Filing Agreement

In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this joint filing agreement is attached, and have duly executed this joint filing agreement as of the date set forth below.

This agreement may be executed in any number of counterparts, each of which shall be deemed an original.

Dated: March 6, 2024